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Society dictates that towards the end of a professional career,
when an individual  reaches a certain chronological age, which varies
with the nations of the world, he or she steps down from his or her posi-
tion to make room for younger people.  For professors at Leiden
University, the tradition has been that they give an inaugural lecture at
the start of their professorial career at which time they try to project a
vision of what they hope to achieve and a farewell lecture when the
term of office comes to an end. The latter occasion is used to look back,
from a personal perspective, at the events that dotted their life’s calen-
dar, reminisce over the persons and personalities who have had a major
impact on their career, reflect  on the extent to which the vision pro-
jected at the beginning was fulfilled, and present some views on what
the future may hold for the field they came to be identified with.  
When I look back at the last 33 years I have spent in Leiden,
roughly thirds of this period as a professor, I feel a great sense of satis-
faction and pleasure. In fact I feel blessed. I came to Leiden on 11th
November 1965 from The Rockefeller University, New York, where I
was doing my post- doctoral work with the now late Prof. Dobzhansky,
one the most famous population geneticists and  one of the most
powerful intellects of this century with whom I had the privilege of
doing my Ph.D at Columbia University, New York, when he was still
there. He instilled in me a sense of how to do science, one which was
to prove very important in all my  career. My scientific work in the
United States was on assessing the adverse genetic consequences of
radiation exposure in populations of fruit flies, namely, Drosophila, a
very favorite experimental organism then as well as now to study this
and several different kinds of problems. Little did I know at that time
that I am going to devote a major part of my scientific career to the
study of genetic consequences of radiation exposure in humans.
The now late Professor Sobels, whom we called Frits and who
headed our  department here till 1987 was instrumental in my coming
to Leiden in 1965.  I did not know him or his work at that time or that
he was one of the greatest scientists in Europe. I first saw his name as
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editor of  a new Journal called Mutation Research in 1964 at the
Rockefeller University library.  Since I had already decided to learn
something more in addition to  population genetics in some other labo-
ratory in the world, the field of mutation research appealed to me.
Further, from the papers he published in the first few issues of
Mutation Research, I knew he was also a Drosophila geneticist.  So, I
corresponded with him, and within three weeks, I was offered a posi-
tion as a senior scientific officer.  In his letter, he noted that my
appointment was for a year and if  I agreed to stay for at least two
years, he could pay the travel expenses for me and my family, one half
when I came and one half when I left. In 1968, the situation changed:
he told me that he would like me to stay permanently here and help him
along with the other colleagues, to build the department and in editing
Mutation Research. I feel so fortunate that I could never collect the
second half of my travel expenses !  
Our relationship transcended the purely professional and the
bonds of friendship and mutual respect became stronger and stronger
with  time. I mention all these because he was the second most impor-
tant person in my career. Frits Sobels was a scientist with vision and he
had one simple philosophy: if you want a build a department, be open
to ideas, get the right kind of people, give them the freedom and a care-
free environment to pursue and sustain their scientific vision, watch
them grow and derive a sense of shared delight in their accomplish-
ments. Paul Lohman who succeeded Frits Sobels not only ensured that
what Frits Sobels built up endured but strengthened it and built on it in
more ways than one.  
Frits Sobels  applied the same philosophy also to the Journal,
Mutation Research which he founded in 1964 and which has grown by
leaps and bounds to become a premier Journal in this ever diversifying
field. A couple of months ago, in its 34th year of existence, we publis-
hed the  400th volume of the Journal. I am proud to be still one of its
editors and this journal remains a part of my life. We grew up together
in Leiden.
The next major  change in my professional life — one that hel-
ped to define my rsearch career for which I am known, came in 1970
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when Frits Sobels recommended my name to be a consultant in gene-
tics to the United Nations Scientific Committee on the Effects of
Atomic Radiation abbreviated as UNSCEAR, a scientific body which
now representss 21 member states. His recommendation was readily
accepted by the then Scientific Secretary of the Committee, Dr.
Francesco Sella, an Italian, who had great confidence in his judgement.
In taking up this assignment, I had the obligation to prove worthy of
their collective confidence in me and do what was expected. The latter
was to critically appraise  and effect a synthesis, in the form of a comp-
rehensive report, of all data in organisms ranging from bacteria to
humans on genetic effects of radiation, draw conclusions on their rele-
vance to the estimation of genetic hazards of radiation exposure of
humans, which the Committee can use for its deliberations. These
reports were subsequently published by the United Nations as official
documents and are considered the most authoritative documents on the
subject.  I have the honor and privilege of serving this Committee since
1970 and being responsible for genetics in the 1972, 1977, 1982, 1986,
1988 and 1993 reports. I am now busy with the millenium report to be
published in the year 2000. 
Judging from the rapid advances occurring in the field of
human genetics with which genetic risk estimation is intimately linked,
and the need to keep abreast of how these are used in risk estimation,
in 1997, the Committee took the step, unprecedented in its 40 year his-
tory, of inviting me, a consultant, to address the whole committee in a
45 minute plenary lecture on advances in genetic risk estimation. I had
the  honor of doing a similar lecture to the Committee, again in 1998
and one further lecture is scheduled for 1999. The  important dividends
of UNSCEAR work, however, are the opportunities to develop a bro-
ader perspective of the whole field of radiation research and get to
know the scientists from all over the world both within and outside the
framework of UNSCEAR.  I still cherish the opportunities this work
had engendered, namely, to visit the laboratories and discuss science
with a number of giants and pioneers who have made phenomenal con-
tributions to the field of radiation genetics and risk estimation. These
include,  Bill and Lee Russell in Oak Ridge, Jim Neel in Ann Arbor,
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K.G. Luning in Sweden, Udo Ehling in Munich, Mary Lyon and Tony
Searle in the United Kingdom  and several others. Friednships with
most of these people have continued to the present.
So, in the mid-1970s, when I was elected to serve as a member
of the Radiobiology Committee of the International Commission on
Radiological Protection or ICRP, it was an other important milestone.
ICRP is another major international organization engaged not only in
the analysis of data on radiation effects, but also in formulating recom-
mendations and guidelines for the protection of man from the hazards
of radiation exposure which are used all over the world. This gave me
an unique opportunity not only to expand my horizons further but also
to look at my science from a different perspective and make new
friends in the fields of radiation epidemiology, radiation dosimetry and
radiation protection from all over the world. It was here I had the ple-
asure of really getting to know Jack Schull from the University of
Texas who along with Jim Neel and several Japanese colleagues  have
done the seminal and most comprehensive of studies on radiation
effects in humans ever done, namely, on the populations of  Hiroshima
and Nagasaki, the victims of A-bomb explosions.  I am proud to count
Jack Schull among my very dear friends with whom, I still have the
pleasure of discussing a wide array of scientific problems and learning
a lot from his very rich experience in the field.  I am both honored and
thrilled to see him here with us today. 
After these personal reminiscences, I  now wish to change
gears and move on to the substance of my presentation today, namely,
emerging perspectives in radiation genetic risk estimation.  I will use
the word “genetic” to mean “hereditary” from now on since genetic is
less cumbersome than hereditary.  There is no need to belabor the fact
that spontaneously-occurring gene mutations and chromosomal aberra-
tions, if they occur  in the germ cells of individuals, can cause genetic
diseases in the progeny or the fact that ionizing radiation has been
found to induce similar  types of changes in all organisms adequately
investigated in this regard.  Putting these two facts together, early on,
it was concluded  that exposure to radiation can cause an increase in the
frequency of genetic diseases in the population. This concept has been
7
and still remains at the core of all our efforts.   The questions that fol-
low are: how much increase?  Is it trivial, small or substantial? Over
how long a period of time? To be sure, these questions are not new, but
they assumed an unprecedented seriousness in the aftermath of World
War II when nuclear weapons were deployed over Hiroshima and
Nagasaki. 
Geneticists have been tackling these questions for nearly 50
years and have been able to provide only provisional answers. The
reasons for this state of affairs are not hard to seek: (i) our goal is to
estimate the risk of radiation-induced genetic diseases in humans; (ii)
we still need to rely on mouse radiation data for this purpose, but these
data are on radiation-induced mutations, but not on genetic  diseases;
extrapolation from mouse to man involves a number of assumptions
and associated uncertainties; (iii)  in the human studies on the children
of survivors of A-bomb explosions in Hiroshima and Nagasaki, no sta-
tistically demonstrable adverse effects of parental radiation exposures
have been found and (iv) laboratory populations of mice, rats and
swine exposed to radiation generation after generation have shown no
progressive deterioration of health and well-being and no accumulation
of harmful mutations with time.
The scientific landscape  is now rapidly changing. We are now
in a much better position than say a few years ago, to integrate the fin-
dings from human and animal studies and explain why in spite of the
compelling evidence for the induction of mutations by radiation in all
biological systems, we have not seen any radiation-induced genetic
disease in humans either in the Japanese or other human studies and
why the animal population studies have been negative. We are now in
a period of transition from the purely classical approaches used thus far
in risk estimation to those which will increasingly include the insights
emerging from a field pivotal  to radiation genetic risk estimation,
namely, human molecular biology;  the latter have already enabled us
to restructure the conceptual framework and reformulate the critical
questions in this field. In order to appreciate as to how this is so, let us
first take a  look  at what genetic risk estimation is about and what we
have achieved using the classical approaches. The general equation
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used for  risk estimation is a good place to start:
Risk per unit dose of radiation = P x [1/DD] x MC
In this equation, P represents the baseline frequency of genetic disea-
ses of interest, 1/DD = relative mutation risk per unit dose and MC =
the responsiveness of the disease class to an increase in mutation rate
and  is called the mutation component.  Let us now examine each one
of these and see where we are.
The quantity P is the baseline frequency of genetic diseases.
These diseases are of three different kinds, namely, mendelian, chro-
mosomal and multifactorial. Mendelian diseases are those due to muta-
tions in single genes and show predictable patterns of inheritance; these
are called mendelian diseases after Mendel who discovered the laws of
heredity.  Examples include,  myotonic dystrophy,  polycystic kidney
disease, cystic fibrosis, hemophilia and Duchenne muscular dystrophy.
Others such as Cri du chat syndrome, Down syndrome, Edwards syn-
drome etc are due to structural or numerical abnormalities of chromo-
somes.  Multifactorial diseases, as the name implies are due to a com-
plex interplay of multiple genes and environmental factors. Examples
include the common congenital abnormalities which are present at
birth such as cleft lip and cleft palate, neural tube defects and chronic
diseases of adults such as diabetes, coronary heart disease, essential
hypertension, allergy, asthma and many others you will be familiar
with. These “run” in families but do not show mendelian patterns of
inheritance i.e., the risk to first-degree relatives is much less than what
is known for mendelian diseases.
Current estimates indicate that about 2.4% of children born
alive are afflicted by one or another mendelian disease, about 0.4%
with detectable chromosomal diseases, and at least 71% with multifac-
torial diseases (i.e., 6% congenital abnormalities and 65% common
chronic diseases).  Note that the multifactorial diseases constitute the
predominant load of genetic diseases which human populations carry.  
The second quantity in the risk equation, 1/DD,  is the relative
mutation risk per unit dose.  The denominator of this fraction,  DD, is
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the abbreviation for what is called the doubling dose i.e., the dose of
radiation that is required to produce as many mutations as those which
arise spontaneously  in a generation.  It can be determined experimen-
tally and is obtained by dividing the average spontaneous mutation rate
in a set of genes by the average rate of induction of mutations in these
genes. Mouse data on coat color mutations have been used for this pur-
pose.  
The DD which has been used until now is 100 rads (= 1 Gy)
for radiation types such as X-rays and gamma rays delivered chroni-
cally or at low doses, the radiation conditions generally used for risk
estimation. Note that since 1/DD is a fraction, a small DD means a high
relative mutation risk and a large DD means a small relative mutation
risk per unit dose.
When I say that the DD is 100 rads, I do not imply that we wish
to make risk estimates at 100 rads which is a pretty large dose.  Our
interest in risk estimation at the population level is at low doses such
as one or a few rads of radiation i.e., of the magnitude one may recei-
ve from diagnostic radiology or from other peaceful uses of nuclear
energy.
The third quantity in the risk equation is MC or the mutation
component. It is a measure of  how  responsive a given class of disea-
ses will be to an increase in mutation rate due to radiation. Because of
differences in the relationship between mutation and disease, the actu-
al MCs as well as the procedures used to estimate them are different for
mendelian and multifactorial diseases. In the case of mendelian disea-
ses,  this relationship is straightforward. Consequently their MC can be
easily estimated on the basis of existing  population genetic theory.  For
multifactorial diseases, howevcr, the relationship between mutation
and disease is complex, and in the absence of theory or models of how
they are maintained in the population, which was the case until recent-
ly, MC could not be estimated and therefore risk prediction was diffi-
cult. 
This situation has now changed.  Within the framework of an
ICRP Task Group, we have been able to develop genetic theory and a
mathematical model to estimate MC for multifactorial diseases. This
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represents an important step forward in risk estimation for these disea-
ses which has remained a neglected territory all these 40 years. Our
results show  that  MC for these diseases is very very small, of the order
of 0.01 to 0.02 in the first generation following radiation exposure.
This means that even if the other two quantities, namely P and 1/DD
remain the same as those used in the earlier years, the risk of multifac-
torial diseases will be very small at low doses of radiation exposure,
compared to their natural prevalence. Two weeks ago, the report of my
Task Group was approved by the main Commission of ICRP in
Stockholm and is scheduled for publication by Elsevier as an official
document; this will set the stage for revisions of genetic risk estimates
in UNSCEAR and for the new recommendations planned to be issued
by ICRP within the next 4 to 5 years.
I now move on to consider how molecular biology has impac-
ted on the field of genetic risk estimation.  Again, as before, a good
place to start is the risk equation:
Risk = P x [1/DD] x MC
As you would recall, P stands for the frequency of the disease class we
are interested in.  The diseases include in P are those that are societal-
ly relevant.  The assumption implicit in multiplying P, by the other two
quantities is that these diseases will increase in frequency as a result of
radiation-induced mutations. Otherwise, it makes no sense in doing
that. Obviously, this can only happen if  spontaneous and radiation
induced changes and the mechanisms of their origin and induction are
similar.  Neither of these appears to be the case.  
Naturally-occuring disease causing mutations include small
changes in the genetic material, the DNA, called point mutations, and
small and large deletions, often limited to the gene. Their mechanisms
of origin  are dependent on the DNA organization of the gene in
question and vary between genes. The sites in the gene at which these
occur are non-random and there are a number of specificites.  
In contrast, although the types of genetic changes induced by
radiation in experimental systems are broadly similar to those which
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underlie naturally-occurring diseases, the radiation spectrum is domi-
nated by multigene deletions. Since radiation produces mutations by
random deposition of energy, one can assume that the probability of
inducing a deletion is the same for all regions of the genome; however,
the probability of  recovering an induced deletion in a viable but affec-
ted livebirth seem more dependent on what gene functions have been
lost and whether such loss is compatible with viability. Further, one
does not expect that radiation  will produce precisely the same specific
types of changes in specific genes which nature has perfected over mil-
lenia. So, the rate of recoverable deletions which are compatible with
viability of livebirths must be much lower than the rate at which they
are originally induced. This is probably the principal, if not the only
reason why induced genetic diseases have not been observed in
humans.
If this were true, how come we have been enormously succes-
sful in radiation mutagenesis studies with a multiplicity of experimen-
tal systems? In retrospect, it is clear that  majority of genes at which
induced mutations have been studied in these systems are non-essential
for survival and also happen to be located in genomic regions which
are non-essential for survival, so that induced mutations could be reco-
vered and studied, an incredibly fortunate coincidence indeed! Not
unexpectedly, studies in which specific point mutations were looked
for or which involved essential genes such as the histocompatibility
genes have been negative. 
You can readily see the implications of these results for the
doubling dose estimate.  Since the DD is a ratio of spontaneous and
induction rates of mutations, if the numerator, namely, the spontaneous
rate stays the same and the denominator, namely the rate of recovera-
ble mutations in the human disease-causing genes is lower than that of
the mouse genes studied,  the DD will become higher. This means
1/DD will be lower than 1/100.  How much lower cannot be said as yet
without further analysis. The real problem is some what more complex.  
Do all these mean that there are no genetic risks of radiation?
Have we been chasing a phantom all these years?  What one can say
now is that the risk of radiation-inducible genetic diseases as perceived
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through the “prism” of  naturally-occuring ones is probably much
smaller than hitherto assumed.  Obviously, with around 80,000 genes
in the human genome, there ought to be genes in our genome which
have the attributes of genes studied in experimental systems in terms of
their response to induced mutations, except that we have not found
them yet. The familiar dictum applies here: if you know what you are
looking for, you may or may not find it. But if you don’t know what
you are looking for, you may never find it.  It is not a phantom chase
since looking for genetic diseases of societal importance and not fin-
ding them provides a sense of reassurance in the minds of geneticists
and public alike.
But there is certainly another side to the whole question of
genetic risks or what I will call alternate reality. As I mentioned earlier,
radiation produces genetic damage in the genome by random deposi-
tion of energy.  This is another way of saying that radiation does not
have the wisdom to know that genetic risk estimators are interested in
diseases of societal importance nor is likely to respect that we have
classified these diseases into mendelian, chromosomal and multifacto-
rial for our convenience. It will produce genetic damage any way.
Some of this damage may be incompatible with viability and will be
eliminated as early embryonic losses or abortions and hence lost to
view.  Some of this damage, however, may be compatible with viabili-
ty and therefore is potentially recoverable in the offspring if one knows
what to look for, bearing in mind that the recoverable damage may be
induced in regions of the genome for which we have, as yet, no “win-
dows”.  How are they likely to manifest themselves? In genetic par-
lance, what are their potential phenotypes?
Some insights into this question come, again, from  human
molecular biology, namely studies of naturally-occurring human
microdeletions. Most, although not all, of these deletions encompass
multiple genes and in molecular terms, can be several megabases of
DNA.  They have been identified because of their clinical phenotypes
in livebirths. Well over 30 of these are known in practically all human
chromosomes, but their distribution is non-random which is to be
expected considering that gene density is not uniform in all chromoso-
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mes.  The important point however is  that despite their occurrence in
different chromosomes they share some common attributes. These are
multisystem developmental abnormalities,  mental retardation, usually
growth retardation and dysmorphic facial features. Since embryonic
development and brain function are two human processes which
depend on the greatest number of genes — which is why fetal brain
cDNA libraries are often used for screening at the molecular level —
it seems plausible that these functions should be the ones most vunera-
ble to loss of function of several genes.
Prompted by these findings with human microdeletions, Bruce
Cattanach and colleagues in England undertook extensive cytogenetic
analyses of growth retarded mice (“runts”) recovered in their mutation
experiments. It was found that between 10 to 15% of these mice had
large multigene deletions or other abnormalities and in different chro-
mosomes; they were non-randomly distributed. The principal inferen-
ces from human and animal studies, therefore, are that  (i) growth and
developmental abnormalities are likely to be among the main manifes-
tations of damage to the genome as a whole although not formally clas-
sified as “genetic diseases”; these are probably more important than
mutations in single genes which the DD method aims to quantify and
(iii) the phenotypes of genomic damage are not necessarily as “clean”
as those of mutations in single genes. Although these arguments seem
compelling, I need to critically examine the available empirical data in
animals and humans in the light of genome organization and function
to reach firm conclusions. This work is underway.
To summarize the principal scientific points of  this lecture: We
now have a model and method, for the first time in 40 years, to make
risk estimation for multifactorial diseases; the estimated risks appear to
be quite low.  I argued that the radiation  risk of mendelian diseases is
probably smaller than assumed until now.  I have presented a case for
taking into account the consequences of genomic damage. Most impor-
tantly, I tried to illustrate how advances in human molecular biology
are reshaping our ideas about genetic risks of radiation exposure and
my firm belief  that progress in genetic risk estimation in the coming
decades is going to be intimately linked to and spearheaded by advan-
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ces in human molecular biology and the development of model systems
such as the mouse which will enable us to delineate gene functions, or
as the molecular biologists call this endeavor, “functional genomics”.
You were exposed to some of the exciting aspects of this field by Rick
Woychik earlier in this symposium.   
I did not present any numerical estimates of risk because the
task of integrating all the available information into a coherent mutu-
ally consistent risk estimate remains.  I am currently working on these.
The international organizations I mentioned earlier and many scientific
colleagues around the world  are very interested in this theme and very
supportive of what I am engaged in so that together we can  set the
stage for further progress in the next decade.  This endeavour is
undoubtedly challenging, but also sometimes frustrating because of
what I call the tyranny of insufficient empirical data.
Soon after his discovery of the mutagenic effects of ionizing
radiation in Drosophila in the late 1920s, for which he received the
Nobel prize for medicine in 1946, Muller started to alert the medical
profession to the genetic consequences of carelessly and avoidably
exposing the human gonads to radiation. Muller was not only one of
the greatest intellects of this century, but also a great humanist; he was
genuinely concerned about human welfare. The field of radiation gene-
tics prospered. From about the mid-1950s onwards, the genetic effects
of radiation effects became an integral component in radiological pro-
tection recommendations by ICRP and other organizations.  Now,
towards the end of this century, the advances in our science suggest that
genetic risks of radiation exposure at low doses are probably not at as
high as Muller feared they might be. I believe that this is an  impor-
tantant achievement of 20th century science.
Ladies and gentlemen, having now come to the end of my lec-
ture it is my pleasant task to thank the authorites of Leiden University,
the Leiden University Medical Centre, Dr. Vermeer, our Dean, the J. A.
Cohen Interuniversity Institute for Radiopathology and Radiation
Protection,  and the members of the department of radiation genetics
and chemical mutagenesis  for  their support and understanding over
these years.  Earlier, I  mentioned the names of some of my teachers
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and colleagues  who have had significant impact on my scientific
career. Now I would like to thank Andrew Czeizel from Budapest who
helped me to broaden my interest and knowledge about human conge-
nital malformations and Ranajit Chakraborty at Houston with whom I
have been, for the past nearly 10 years,  re-exploring population gene-
tics which was my first passion when I started doing science in the
1960s. Ranajit is a brilliant  population geneticist and a great friend.
Together,  we have been able to build mathematical models for estima-
ting the risk of multifactorial diseases which I mentioned in my lectu-
re  and also  for assessing the impact of genetic  predisposition to can-
cer on  radiation cancer risks, one of the current problems in radiation
carcinogenesis which I did not have time to go into in this lecture. I
thank him most heartily for all that I was able to learn from him.  
I am deeply grateful to  Natarajan, my colleague here, for per-
sonally helping me to admire the magical kingdom of mammalian
cytogenetics several years ago, and Paul van Buul who helped me to
carry out several joint cytogenetic studies.  The common denominators
in my Drosophila and mammalian cytogenetic work are Annemarie van
Duyn and Marjan Loos whose diligence and care in the conduct of
experiments were responsible for what ever I was able to do in these
fields. Jane Pleging is, and Joost van Urk was until she retired recent-
ly, a great help at the secretariat, especially when I came up with enor-
mous manuscripts and tables for typing which they cheerfully did.
Anton de Groot and Mathieu Niericker have helped me immensely at
critical junctures when I panicked in ignorance when my computer did
not do what I wanted it to do and Theo Wand, our photographer, who
has made good quality slides for me for over 30 years for my lectures
all over the world, including the ones you are seeing today. He is a
loyal friend.  To all of them,  I am very grateful. 
The pursuit of science always costs money and over more than
2 decades, the commission of the European communities, now the
European union, has generously supported my scientific research; for a
period of three years, I had also the good fortune of receiving a grant
from the Atomic Energy Control Board of Canada in Ottawa.   
I wish to thank Paul Lohman, Wouter Ferro and Marijke
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Steenbergen, Albert Pastink, Bert van Zeeland and Margaret
Zdzienicka of our lab and Wim Passchier from the Health Research
Council of The Netherlands,  for planning and organizing  this occa-
sion, the MGC, Gezondheidsraad, IRS, Leiden University and Elsevier
which lent financial support to make this possible; I am very much
indebted to all the speakers and the chairmen and the members of the
audience who took time off from their busy schedules to be here today.
Finally, human genomes as all others, need a proper environment to
function effectively, starting with home. I would certainly not have
been able to pursue my dreams in science without the unfailing support
and the environment created by Kokila,  my wife of 41 years and our
4 children. In fact, I feel blessed in this respect. Despite our Indian
genomes and the associated phenotypes, we do feel “Dutch”, a tribute
to the great qualities of assimilation in this country. I do share with my
family the overall concept “it ain’t much if it ain’t Dutch” although I
would not want to discuss it elsewhere.  Thank you all very much for
your patience.
